Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137601 | 0.84 | KMT2A (0.36) | KMT2A | |
| SCHEMBL21137606 | 0.82 | ACHE (0.49) | ALDH1A1LMNA | |
| SCHEMBL9547614 | 0.82 | HTT (0.45) | KMT2ATSHRALOX15MEN1ALDH1A1 | |
| SCHEMBL8908473 | 0.82 | POLB (0.33) | KMT2ATSHRALOX15EPHX1GAA | |
| SCHEMBL15176884 | 0.82 | KMT2A (0.40) | KMT2ATSHRCYP2C19MEN1ALDH1A1 | |
| SCHEMBL29100482 | 0.80 | GBA1 (0.33) | TSHRALOX15GBA1 | |
| SCHEMBL12207797 | 0.80 | POLB (0.42) | KMT2AEPHX1MEN1ALDH1A1POLB | |
| SCHEMBL15949860 | 0.80 | KMT2A (0.44) | KMT2ATSHRCYP2C19MEN1ALDH1A1 | |
| SCHEMBL22747912 | 0.79 | KDM4E (0.38) | TSHRALOX15LMNACYP3A4NFKB1 | |
| SCHEMBL31662525 | 0.79 | TSHR (0.32) | TSHRALOX15ALDH1A1GAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11707531-B2 | Compounds, compositions, and methods for the treatment of disease | F-star Therapeutics, Inc. (GB) | 2023-07-25 | — | — | US | disclosed |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2023-04-20 | — | — | US | disclosed |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2021-10-07 | — | — | US | disclosed |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200268899-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
| US-9173966-B2 | Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130287699-A1 | Luciferin Derivatives from Bicyclic Reactants and Aminothiol Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-31 | — | — | US | disclosed |
| US-8343477-B2 | Viricides; serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | KTB TUMORFORSCHUNGSGESELLSCHAFT MBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-7741281-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-22 | — | — | US | disclosed |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-08 | — | — | US | disclosed |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | BRISTOL-MYERS SQUIBB COMPANY | 2007-05-03 | — | — | US | disclosed |
| US-7173004-B2 | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287699-A1 | Luciferin Derivatives from Bicyclic Reactants and Aminothiol Derivatives and Methods of Use Thereof | GFPT1, QPCT, GLB1 | KMT2A 4015/4885TSHR 3747/4885ALOX15 1198/4885 |
| US-20080107623-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | KMT2A 4411/4885TSHR 1242/4885ALOX15 4708/4885 |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | KMT2A 4577/4885TSHR 2042/4885ALOX15 148/4885 |
| US-20070099825-A1 | ethyl 2-(biphenyl-4-yl)-6-(tert-butoxycarbonylamino)-2-methoxy-8-(2-nitrophenylsulfonyl)-5,16-dioxo-1,2,3,5,6,7,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[n]pyrrolo[2,1-c][1,4,8]triazacyclopentadecine-14a-carboxylate; viricide; synergistic with other active ingredients | TERT, VIP, YWHAZ | KMT2A 3526/4885TSHR 691/4885ALOX15 2040/4885 |
| US-20080107624-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, MRPS23, HCCS | KMT2A 4324/4885TSHR 1168/4885ALOX15 4731/4885 |
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | KMT2A 4577/4885TSHR 2042/4885ALOX15 148/4885 |
| US-20090324544-A1 | SUBSTITUTED CYCLIC PYRROLIDINE DERIVATIVES | EIF2AK2, NSUN2, RNMT | KMT2A 3226/4885TSHR 4282/4885ALOX15 2493/4885 |
| US-20120142711-A1 | ACID-LABILE TRIGGER UNITS | ASIC1, ABL1, CA9 | KMT2A 4093/4885TSHR 2445/4885ALOX15 648/4885 |
| US-20230121556-A1 | COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASE | LTB4R, LTC4S, LTA4H | KMT2A 3320/4885TSHR 3547/4885ALOX15 444/4885 |
| US-20080004272-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | KMT2A 2807/4885TSHR 4021/4885ALOX15 2697/4885 |
| US-11707531-B2 | Compounds, compositions, and methods for the treatment of disease | STING1, MAVS, IRF3 | KMT2A 4473/4885TSHR 3765/4885ALOX15 445/4885 |
| US-20200268899-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, MAVS, IRF3 | KMT2A 4473/4885TSHR 3765/4885ALOX15 445/4885 |
| US-20080107625-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, VIP | KMT2A 4411/4885TSHR 1242/4885ALOX15 4708/4885 |
| US-20210308207-A1 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | VIP, PIN1, QPCT | KMT2A 4410/4885TSHR 1438/4885ALOX15 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.